Menarini group and liver therapeutics, relapsed pre-treatment therapy, reactive, nonresponsive aggressive B cells, non-hyozycin lymphoma target doping tips ((MEN1703, SEL24) JASPIS-01 clinical secondary first data published by 2026 ASH annual scientific journal

Summary

The first clinical data of the l-dapoletic tip single therapy: all available standard treatment options are the first results of a JASPIS-01 clinical secondary study evaluating the kinase inhibitor dapoletictip (dapolsertib, MEN1703) amongst class 1 trajectory PIM/FLT3 targeted at patients with degenerative relapsing, nonresponsive, aggressive B cell non-hypocyte lymphoma (B-NHL).